+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Global Haemophilia Treatment Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • PDF Icon

    Report

  • 210 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5451227

To replace the missing blood clotting factor so that the blood can clot properly

The Global Haemophilia Treatment Market is estimated to be USD 14.33 Bn in 2023 and is expected to reach USD 19.34 Bn by 2028 growing at a CAGR of 6.19%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding the growth and reducing the risks.

Market Segmentations

  • The Global Haemophilia Treatment Market is segmented based on Product, Disease Indication, Distribution Channel, and Geography.
  • By Product, the market is classified into Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, and Extended Half-Life Products.
  • By Disease Indication, the market is classified into Haemophilia A, Haemophilia B, and Haemophilia C.
  • By Distribution Channel, the market is classified into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa, and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Bayer Ag, Pfizer Inc., CSL Behring, BioMarin, Octopharma Ag, Genzyme Corp., Spark Therapeutics Inc., Baxter International, Grifols S.A., etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Haemophilia Treatment Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Haemophilia Treatment Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Haemophilia Treatment Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 and the impact of economic slowdown & impending recession on the market are also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Prevelence of Haemophilia
4.1.2 Expansion of Hemostats for Wound Closure
4.1.3 Advancements in Drug Delivey
4.2 Restraints
4.2.1 High Cost of Recombinant Products
4.3 Opportunities
4.3.1 Rising R&D and New Product Development
4.3.2 Adavncements in Rare Disease Gene Therapy
4.4 Challenges
4.4.1 Lack of Awareness in Developing and Under-Developed Countries
4.4.2 Adverse Effects Associated with Plasma-Derived Products
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Impact of Economic Slowdown & Impending Recession
5.6 Ansoff Matrix Analysis
6 Global Haemophilia Treatment Market, By Product
6.1 Introduction
6.2 Recombinant Coagulation Factor
6.3 Plasma-Derived Coagulation Factor
6.4 Extended Half-Life Products
7 Global Haemophilia Treatment Market, By Disease Indication
7.1 Introduction
7.2 Haemophilia A
7.3 Haemophilia B
7.4 Haemophilia C
8 Global Haemophilia Treatment Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
9 Americas' Haemophilia Treatment Market
9.1 Introduction
9.2 Argentina
9.3 Brazil
9.4 Canada
9.5 Chile
9.6 Colombia
9.7 Mexico
9.8 Peru
9.9 United States
9.10 Rest of Americas
10 Europe's Haemophilia Treatment Market
10.1 Introduction
10.2 Austria
10.3 Belgium
10.4 Denmark
10.5 Finland
10.6 France
10.7 Germany
10.8 Italy
10.9 Netherlands
10.10 Norway
10.11 Poland
10.12 Russia
10.13 Spain
10.14 Sweden
10.15 Switzerland
10.16 United Kingdom
10.17 Rest of Europe
11 Middle East and Africa's Haemophilia Treatment Market
11.1 Introduction
11.2 Egypt
11.3 Israel
11.4 Qatar
11.5 Saudi Arabia
11.6 South Africa
11.7 United Arab Emirates
11.8 Rest of MEA
12 APAC's Haemophilia Treatment Market
12.1 Introduction
12.2 Australia
12.3 Bangladesh
12.4 China
12.5 India
12.6 Indonesia
12.7 Japan
12.8 Malaysia
12.9 Philippines
12.10 Singapore
12.11 South Korea
12.12 Sri Lanka
12.13 Thailand
12.14 Taiwan
12.15 Rest of Asia-Pacific
13 Competitive Landscape
13.1 Competitive Quadrant
13.2 Market Share Analysis
13.3 Strategic Initiatives
13.3.1 M&A and Investments
13.3.2 Partnerships and Collaborations
13.3.3 Product Developments and Improvements
14 Company Profiles
14.1 Baxter International
14.2 Bayer Ag
14.3 Biogen Idec Inc.
14.4 BioMarin
14.5 Chugai Pharmaceutical Co. Ltd.
14.6 CSL Behring
14.7 Genzyme Corp.
14.8 Grifols S.A.
14.9 Hospira Inc.
14.10 Kedrion
14.11 Novo Nordisk AS
14.12 Octopharma Ag
14.13 Pfizer Inc.
14.14 Shire
14.15 Spark Therapeutics Inc.
15 Appendix
15.1 Questionnaire

Companies Mentioned

  • Baxter International
  • Bayer Ag
  • Biogen Idec Inc.
  • BioMarin
  • Chugai Pharmaceutical Co. Ltd.
  • CSL Behring
  • Genzyme Corp.
  • Grifols S.A.
  • Hospira Inc.
  • Kedrion
  • Novo Nordisk AS
  • Octopharma Ag
  • Pfizer Inc.
  • Shire
  • Spark Therapeutics Inc.

Table Information